Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
From Bristol Myers Squibb
Via Business Wire
Tickers BMY TPTX
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY TSVT
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow’s Innovators Program to Increase Black Representation in the Healthcare Industry
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.